Universe Pharmaceuticals INC
UPC
$5.94
-$1.15-16.22%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 17.74M | 17.80M | 17.86M | 18.58M | 19.29M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 17.74M | 17.80M | 17.86M | 18.58M | 19.29M |
| Cost of Revenue | 11.26M | 11.41M | 11.56M | 12.49M | 13.43M |
| Gross Profit | 6.48M | 6.39M | 6.30M | 6.08M | 5.87M |
| SG&A Expenses | 7.90M | 8.22M | 8.55M | 9.99M | 11.43M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | 800.00 | 1.60K |
| Total Operating Expenses | 19.83M | 20.30M | 20.77M | 24.34M | 27.90M |
| Operating Income | -2.09M | -2.50M | -2.92M | -5.76M | -8.61M |
| Income Before Tax | -1.94M | -2.81M | -3.67M | -6.68M | -9.68M |
| Income Tax Expenses | -- | -- | -- | -29.20K | -58.40K |
| Earnings from Continuing Operations | -1.94 | -2.81 | -3.67 | -6.65 | -9.62 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.94M | -2.81M | -3.67M | -6.65M | -9.62M |
| EBIT | -2.09M | -2.50M | -2.92M | -5.76M | -8.61M |
| EBITDA | -1.61M | -2.00M | -2.40M | -5.25M | -8.10M |
| EPS Basic | -3.45 | -6.79 | -8.32 | -153.58 | -298.84 |
| Normalized Basic EPS | -2.15 | -4.24 | -5.20 | -96.77 | -188.34 |
| EPS Diluted | -3.45 | -6.79 | -8.32 | -153.58 | -298.84 |
| Normalized Diluted EPS | -2.15 | -4.24 | -5.20 | -96.77 | -188.34 |
| Average Basic Shares Outstanding | 2.25M | 2.04M | 2.04M | 1.50M | 954.70K |
| Average Diluted Shares Outstanding | 2.25M | 2.04M | 2.04M | 1.50M | 954.70K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |